ATN-103 + methotrexate

ATN-103 + methotrexate is a **combination therapy** comprising ATN-103, a monoclonal antibody targeting tumor necrosis factor alpha (TNFα), and methotrexate, a small molecule antimetabolite and immunosuppressant. ATN-103 inhibits circulating TNFα, thereby reducing inflammation and immune activity, while methotrexate acts as a folate antagonist, suppressing immune cell proliferation and exerting broad anti-inflammatory effects. The combination is typically investigated for use in autoimmune diseases, most notably **rheumatoid arthritis**, aiming to leverage synergistic immunomodulatory effects for enhanced disease control, especially in patients who have inadequate response to methotrexate alone.

Other names

ATN-103ATN103ATN 103